Understanding triclabendazole resistance

DSpace/Manakin Repository

Search OPUS

Advanced Search


My Account

Show simple item record

dc.contributor.author Brennan, GP
dc.contributor.author Fairweather, I
dc.contributor.author Trudgett, A
dc.contributor.author Hoey, E
dc.contributor.author McCoy, C
dc.contributor.author McConville, M
dc.contributor.author Meaney, M
dc.contributor.author Robinson, MW
dc.contributor.author McFerran, N
dc.contributor.author Ryan, LA
dc.contributor.author Lanusse, C
dc.contributor.author Mottier, L
dc.contributor.author Alvarez, L
dc.contributor.author Solana, H
dc.contributor.author Virkel, G
dc.contributor.author Bronphy, PM
dc.date.accessioned 2010-05-28T09:50:47Z
dc.date.issued 2007-01
dc.identifier.citation Experimental and Molecular Pathology, 2007, 82 (2), pp. 104 - 109
dc.identifier.issn 0014-4800
dc.identifier.other C1UNSUBMIT en_US
dc.identifier.uri http://hdl.handle.net/10453/9614
dc.description.abstract Triclabendazole (TCBZ) has been the drug of choice to treat liver fluke infections in livestock for > 20 years, due to its high activity against both adult and juvenile flukes. More recently, it has been used successfully to treat human cases of fascioliasis. Resistance to TCBZ first appeared in the field in Australia in the mid-1990s. Since then, resistance has been reported from a number of countries throughout Europe: Ireland, Scotland, Wales, Spain and The Netherlands. The heavy reliance on a single drug puts treatment strategies for fascioliasis at risk. Should resistance develop further, the prospect is an alarming one. This review will present an overview of progress in understanding the mechanism of resistance to TCBZ, examining possible changes in the target molecule, in drug influx/efflux mechanisms and in the metabolism of TCBZ by the fluke. The review will also consider ways to deal with resistance, covering drug-oriented options such as: the use of alternative drugs, drug combinations and the search for new compounds.
dc.publisher Elsevier
dc.relation.isbasedon 10.1016/j.yexmp.2007.01.009
dc.title Understanding triclabendazole resistance
dc.type Journal Article
dc.parent Experimental and Molecular Pathology
dc.journal.volume 2
dc.journal.volume 82
dc.journal.number 2 en_US
dc.publocation Amsterdam, The Netherlands en_US
dc.identifier.startpage 104 en_US
dc.identifier.endpage 109 en_US
dc.cauo.name SCI.Institute for Biotechnology of Infectious Diseases en_US
dc.conference Verified OK en_US
dc.for 0707 Veterinary Sciences
dc.personcode 100777
dc.personcode 100991
dc.percentage 100 en_US
dc.classification.name Clinical Sciences en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords Triclabendazole; Fasciola hepatica; Resistance; ?-Tubulin isotype; Molecular modeling; P-glycoprotein; Drug metabolism; Proteomics en_US
dc.description.keywords Triclabendazole
dc.description.keywords Fasciola hepatica
dc.description.keywords Resistance
dc.description.keywords ?-Tubulin isotype
dc.description.keywords Molecular modeling
dc.description.keywords P-glycoprotein
dc.description.keywords Drug metabolism
dc.description.keywords Proteomics
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Arts and Social Sciences
pubs.organisational-group /University of Technology Sydney/Faculty of Arts and Social Sciences/Education Group
pubs.organisational-group /University of Technology Sydney/Faculty of Science
utslib.copyright.status Closed Access
utslib.copyright.date 2015-04-15 12:17:09.805752+10
utslib.collection.history Closed (ID: 3)

Files in this item

This item appears in the following Collection(s)

Show simple item record